GlassScriptPhysician profile
Sara Higbee
NPI 1659035582
$8,953.03
in general payments reported to CMS, 2019-2025
20 companies · $6,457 in 2025
The $6,457 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $391 · 2023: $1,015 · 2024: $1,090 · 2025: $6,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,495 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,772 · Education: $294 · Travel and Lodging: $1.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,494.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,772.00 |
| Education | $293.50 |
| Travel and Lodging | $1.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,588.35 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,646.68 | 2022-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $707.56 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $530.44 | 2023-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $444.20 | 2023-2025 | Dupixent |
| Verona Pharma, INC. | $398.46 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $310.35 | 2023-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Insmed, INC. | $300.01 | 2024-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $254.74 | 2025 | Orenitram, Remodulin, Tyvaso |
| Sanofi-Aventis U.S. LLC | $159.98 | 2023-2025 | |
| Amgen INC. | $137.50 | 2024-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $133.48 | 2024-2025 | Opsumit, Uptravi |
| Ani Pharmaceuticals, INC. | $86.73 | 2024-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $75.29 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $69.52 | 2023 | Glassia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $31.85 | 2022-2023 | Xolair |
| Mylan Specialty L.P. | $24.18 | 2023 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $20.79 | 2025 | Eliquis |
| Circassia INC. | $17.55 | 2025 | Niox |
| Janssen Pharmaceuticals, INC | $15.37 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Higbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.